CV Sciences, Inc. (OTCQB:CVSI) Q1 2025 - Earnings Conference Call May 14, 2025 4:00 PM ET Company Participants Brendan Hawkins - IR Joseph Dowling - CEO Joerg Grasser - CFO Conference Call Participants Operator Greetings, and welcome to CV Sciences' First Quarter 2025 Earnings Conference Call. At this time, participants are in a listen only mode.
CV Sciences, Inc. (OTCQB:CVSI) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Brendan Hawkins - Investor Relations Joseph Dowling - Chief Executive Officer Joerg Grasser - Chief Financial Officer Conference Call Participants Operator Greetings and welcome to the CV Sciences' Fourth Quarter and Year-End 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
CV Sciences, Inc. (OTCQB:CVSI) Q3 2024 Earnings Conference Call November 14, 2024 10:00 AM ET Company Participants Brendan Hawkins - Investor Relations Joseph Dowling - Chief Executive Officer Joerg Grasser - Chief Financial Officer Operator Greetings, and welcome to the CV Sciences Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
18 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
18 Aug 2025 (In 3 weeks) Date | | - Cons. EPS | - EPS |
12 May 2025 Date | | - Cons. EPS | - EPS |
26 Mar 2025 Date | | - Cons. EPS | - EPS |
12 Nov 2024 Date | | - Cons. EPS | - EPS |
13 Aug 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Joseph D. Dowling CEO | OTCQB Exchange | US1266541028 ISIN |
United States Country | 42 Employees | - Last Dividend | - Last Split | - IPO Date |
CV Sciences, Inc., established in San Diego, California, since its inception in 2010, stands as a significant player in the North American market for herbal supplements and hemp-based cannabidiol (CBD) products. Initially known as CannaVest Corp., the company underwent a name change to CV Sciences, Inc. in January 2016, reflecting its broader commitment to scientific innovation within the CBD industry. The company’s operations encompass the development, manufacturing, marketing, and sale of a variety of CBD-based products and it is also pioneering cannabinoids for potential medical use. It caters to various sectors of the health care market including nutraceuticals, beauty care, specialty foods, and pet products, distributing its offerings through a spectrum of channels including its own websites, select distributors, brick-and-mortar retailers, and certain e-tailers.